All In Biotech

Drug Trial Radar · NCT00048932

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Nov 24, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,795 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,795

Actual

Start

Dec 2002

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 13, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study is to learn if abatacept is safe when co-administered with other approved rheumatoid arthritis medications.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Double-blind AbataceptDrug

    Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Day 1, 15, and 29.

  • Double-blind PlaceboDrug

    Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.

  • Open-label AbataceptDrug

    Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Every 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double Blind Period (DB); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to DiscontinuationTime frame: Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication
  2. DB; Number of Participants With AEs of Special InterestTime frame: Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication
  3. DB; Number of Participants With Hematology Laboratories Meeting Marked Abnormality CriteriaTime frame: Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication
  4. DB; Number of Participants With Blood Chemistry Laboratories Meeting Marked Abnormality (MA) CriteriaTime frame: Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication
  5. DB; Number of Participants With Clinically Significant Physical Examination or Vital Signs AbnormalitiesTime frame: Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337. Vital signs were measured at these visits before and after study medication infusion.
  6. Open Label Period (OL); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to DiscontinuationTime frame: Day 365 to Day 1,821
  7. OL; Number of Participants With AEs of Special InterestTime frame: Day 365 to Day 1821
  8. OL; Number of Participants With Hematology Laboratories Meeting Marked Abnormality CriteriaTime frame: Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication
  9. OL; Number of Participants With Liver Function Laboratories Meeting Marked Abnormality CriteriaTime frame: Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication
  10. OL; Number of Participants With Electrolyte Laboratories Meeting Marked Abnormality CriteriaTime frame: Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication
  11. OL; Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting Marked Abnormality CriteriaTime frame: Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication
  12. OL; Number of Participants With Clinically Significant Physical Examination or Vital Signs AbnormalitiesTime frame: Days 365 to Day 1821

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution

    Decatur, Alabama

  • Local Institution

    Paradise, Arizona

  • Local Institution

    Phoenix, Arizona

  • Local Institution

    Tucson, Arizona

  • Local Institution

    San Francisco, California

  • Local Institution

    Loveland, Colorado

  • Local Institution

    Hamden, Connecticut

  • Local Institution

    Lake Worth, Florida

  • Local Institution

    Largo, Florida

  • Local Institution

    Blairsville, Georgia

  • Local Institution

    Chicago, Illinois

  • Local Institution

    Evansville, Indiana

  • Local Institution

    Indianapolis, Indiana

  • Local Institution

    Wichita, Kansas

  • Local Institution

    Louisville, Kentucky

  • Local Institution

    New Orleans, Louisiana

  • Local Institution

    Baltimore, Maryland

  • Local Institution

    Cumberland, Maryland

  • Local Institution

    Westminster, Maryland

  • Local Institution

    Boston, Massachusetts

  • Local Institution

    Grand Rapids, Michigan

  • Local Institution

    Royal Oak, Michigan

  • Local Institution

    Toms River, New Jersey

  • Local Institution

    Los Alamos, New Mexico

  • Local Institution

    New York, New York

  • Local Institution

    Durham, North Carolina

  • Local Institution

    Hickory, North Carolina

  • Local Institution

    Canton, Ohio

  • Local Institution

    Cleveland, Ohio

  • Local Institution

    Columbus, Ohio

  • Local Institution

    Elyria, Ohio

  • Local Institution

    Youngstown, Ohio

  • Local Institution

    Oklahoma City, Oklahoma

  • Local Institution

    Wyomissing, Pennsylvania

  • Local Institution

    Columbia, South Carolina

  • Local Institution

    Sioux Falls, South Dakota

  • Local Institution

    Ducktown, Tennessee

  • Local Institution

    Nashville, Tennessee

  • Local Institution

    Richmond, Virginia

  • Local Institution

    Edmonds, Washington

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.